Quick Answer
Immix Biopharma, Inc. reported Net Income of -$29.44 million for fiscal year 2025.
Immix Biopharma, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$29.44M -36.2% |
-$21.61M -40.1% |
-$15.43M -87.4% |
-$8.23M +66.2% |
-$24.38M -2024.3% |
-$1.15M |
| Diluted EPS | -$0.89 -17.1% |
-$0.76 +14.6% |
-$0.89 -50.8% |
-$0.59 | — | — |
| Total Assets | $104.84M +356.9% |
$22.95M +15.2% |
$19.93M +33.7% |
$14.91M -18.1% |
$18.19M +3271.4% |
$539.6K |
| Cash and Equivalents | $93.93M +431.2% |
$17.68M +1.0% |
$17.51M +30.3% |
$13.44M -23.8% |
$17.64M +4411.7% |
$391.1K |
| Stockholders Equity | $93.80M +607.8% |
$13.25M -19.2% |
$16.41M +24.7% |
$13.16M -26.8% |
$17.99M +480.3% |
-$4.73M -29.7% |
| R&D Expense | $16.26M +44.0% |
$11.29M +29.3% |
$8.74M +108.2% |
$4.20M +3216.1% |
$126.5K -49.0% |
$248.1K |
| Operating Income | -$29.96M -32.1% |
-$22.67M -40.5% |
-$16.14M -96.4% |
-$8.22M -507.9% |
-$1.35M -197.9% |
-$453.9K |
| Shares Outstanding | 52.95M +92.3% |
27.54M +38.2% |
19.92M +43.4% |
13.89M +5.0% |
13.23M +292.0% |
3.38M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$7.59M | -6.1% | -14.5% |
| Diluted EPS | September 30, 2025 | -$0.24 | +0.0% | -9.1% |
| Total Assets | September 30, 2025 | $20.08M | -20.1% | +28.4% |
| Cash and Equivalents | September 30, 2025 | $15.95M | -19.0% | +37.0% |
| Stockholders Equity | September 30, 2025 | $8.26M | -52.9% | +77.6% |
| R&D Expense | September 30, 2025 | $4.58M | +3.1% | +15.4% |
| Operating Income | September 30, 2025 | -$7.66M | -3.6% | -14.1% |
| Shares Outstanding | September 30, 2025 | 33.04M | +20.2% | +16.3% |
- Immix Biopharma, Inc. reported Net Income of -$29.44 million for fiscal year 2025.
- Immix Biopharma, Inc. showed a decrease of -36.2% in Net Income compared to the prior fiscal year.
- Immix Biopharma, Inc. reported Diluted EPS of $0.89 per share (loss) for fiscal year 2025.
- Immix Biopharma, Inc. showed a decrease of -17.1% in Diluted EPS compared to the prior fiscal year.
- Immix Biopharma, Inc. reported Total Assets of $104.84 million for fiscal year 2025.
- Immix Biopharma, Inc. showed an increase of +356.9% in Total Assets compared to the prior fiscal year.
- Immix Biopharma, Inc. reported Cash and Equivalents of $93.93 million for fiscal year 2025.
- Immix Biopharma, Inc. showed an increase of +431.2% in Cash and Equivalents compared to the prior fiscal year.
- Immix Biopharma, Inc. reported Stockholders Equity of $93.80 million for fiscal year 2025.
- Immix Biopharma, Inc. showed an increase of +607.8% in Stockholders Equity compared to the prior fiscal year.
- Immix Biopharma, Inc. reported R&D Expense of $16.26 million for fiscal year 2025.
- Immix Biopharma, Inc. showed an increase of +44.0% in R&D Expense compared to the prior fiscal year.
- Immix Biopharma, Inc. reported Operating Income of -$29.96 million for fiscal year 2025.
- Immix Biopharma, Inc. showed a decrease of -32.1% in Operating Income compared to the prior fiscal year.
- Immix Biopharma, Inc. reported Shares Outstanding of 52.95 million shares for fiscal year 2025.
- Immix Biopharma, Inc. showed an increase of +92.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: